BG
KBIO

BlackRock Group’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

BlackRock Group’s Portfolio KBIO Stock Details KBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-4,395
Closed -$159K – 2985
2013
Q3 		$159K Buy
+4,395
New +$200K ﹤0.01% 2536

Other funds holding KBIO

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
LBH
Lehman Brothers Holdings New York $794K AUM 28.79% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

BlackRock Group's KBIO Position: Q4 2013 in Review

BlackRock Group sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q4 2013, closing a stake of 4,395 shares — an estimated $159K sold.

BlackRock Group first reported a position in KBIO in Q3 2013 and held it in 1 quarter. The position peaked at $159K in Q3 2013. 46 funds tracked by Wall St. Rank hold KBIO as of Q4 2013.

  • BlackRock Group reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q4 2013 after selling out during the quarter.
  • BlackRock Group sold 4,395 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q4 2013, an estimated $159K.
  • BlackRock Group first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q3 2013 and held it in 1 quarter.
  • BlackRock Group's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $159K in Q3 2013.
  • 46 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q4 2013.

Based on BlackRock Group's 13F filing for Q4 2013, filed 12 Feb 2014.